Effect of donepezil on motor and cognitive function in Huntington disease

Neurology

Volumn 67, Issue 7, 2006, Pages 1268-1271

  Cubo, E ^a,b,c   Shannon, K M ^a   Tracy, D ^a   Jaglin, J A ^a   Bernard, B A ^a   Wuu, J ^a   Leurgans, S E ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CERVICAL SPINE FRACTURE; CHOREA; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LONGITUDINAL STUDY; MALE; MOTOR DYSFUNCTION; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAMPLE; SIDE EFFECT; SUICIDAL IDEATION;

CHOREA; COGNITION DISORDERS; FEMALE; HUMANS; HUNTINGTON DISEASE; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PIPERIDINES; PLACEBO EFFECT; QUALITY OF LIFE; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 33749861388     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000238106.10423.00     Document Type: Article

References (10)

1. O'Suilleabhain P, Dewey RB. A randomized trial of amantadine in Huntington's disease. Arch Neurol 2003;60:996-998.
2. Duan W, Guo Z, Jiang H, Ladenheim B, et al. Paroxetine retards disease onset and progression in Huntington mutant mice. Ann Neurol 2004;55:590-594.
3. Chari S, Quraishi SH, Jainer AK. Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report. Pharmacopsychiatry 2003;36:41-43.
4. Lange KW, Javoy-Agid F, Agid Y, et al. Brain muscarinic cholinergic receptors in Huntington's disease. J Neurol 1992;239:103-104.
5. de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004;19:1516-1518.
6. Fernandez HH, Friedman JH, Grace J, et al. Donepezil for Huntington's disease. Mov Disord 2000;15:173-176.
7. Petrikis P, Andreou C, Piachas A, et al. Treatment of Huntington's disease with galantamine. Int Clin Psychopharmacol 2004;19:49-50.
8. Zhou FM, Wilson C, Dani JA. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003;9:23-36.
9. Bonelli RM, Thau K. Noncompliance: an overview. Dtsch Med Wochenschr 2001;126:699-703.
10. Aarsland D, Laake K, Larsen JP, et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-712.